Skip to main content
    B

    BioAge Labs, Inc (BIOA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $5.35
    -0.07 (-1.29%)

    Market Cap: $248.76M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(3/8)
    Avg Surprise
    -109.53%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.61
    Range$-0.69 - $-0.42
    7 analysts
    EPS Revisions
    3
    0
    7d
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.66+7.4%
    60d ago$-0.66+7.4%
    30d ago$-0.610.0%
    7d ago$-0.610.0%
    Current$-0.61
    Revenue Consensus
    $2M
    Range$0 - $3M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.51
    Range$-0.91 - $-0.08
    7 analysts
    Revenue Consensus
    $3M
    Range$1M - $6M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.51---
    Sep 26EST
    		-$-0.61---
    Jun 26
    Reported Aug 6
    		$-0.58$-0.65+10.77%Beat+3.3%
    Mar 26
    Reported May 8
    		$-0.52$-0.71+26.76%Beat-44.4%
    Dec 25
    Reported Mar 24
    		$-0.72$-0.67-7.69%Miss+28.0%
    Sep 25
    Reported Nov 6
    		$-0.56$-0.51-9.80%Miss+91.6%
    Jun 25
    Reported Aug 6
    		$-0.60$-0.38-57.89%Miss+0.0%
    Mar 25
    Reported May 6
    		$-0.36$-0.53+32.08%Beat-
    Dec 24
    Reported Mar 20
    		$-1.00$-0.66-52.67%Miss-
    Sep 24
    Reported Nov 7
    		$-6.70$-0.73-817.81%Miss-
    Jun 24
    Reported Sep 26
    		$-0.60$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.25EV/EBITDAN/A
    Price/FCF-2.72xFCF Yield-36.72%
    Profitability
    Profit Margin0.00%Operating Margin-1197.00%
    ROE-28.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-378.19x
    Current Ratio17.19xQuick Ratio17.19x
    Trading Statistics
    Beta1.08Avg Volume894.21K
    52-Week High$25.9552-Week Low$5.04

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.04
    SMA 20$6.77
    SMA 50$8.56
    SMA 200$16.38
    EMA 10$6.03
    EMA 20$6.74
    EMA 50$9.24
    EMA 200$13.21

    MACD

    Line: -1.04Signal: -1.07Hist: 0.02

    ADX

    ADX: 48.5+DI: 11.5-DI: 41.1

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$6.18

    Bollinger Bands

    Upper Band$8.56
    Lower Band$4.97
    %B Position5313%(Upper)
    Band Width0.11

    RSI (14-Day)

    Oversold
    19.3

    Momentum Oscillators

    Stoch %K2.5
    Stoch %D3.5
    Williams %R-96.7
    ROC (10d)-21.4%
    Momentum-1.46
    CCI (20d)-130.2
    MFI (14d)19.2

    Volatility Measures

    ATR (14d)$0.46(8.6%)
    StdDev (20d)0.90
    Hist Vol51.9%(High)

    Volume Flow

    VWAP$5.38
    OBV-7.5M
    AD Line3.4M
    CMF (20d)-0.101

    Volume Metrics

    Avg Vol (20d)900.8K
    Vol Ratio0.9x
    VWMA (20d)$6.80

    Pivot Points

    R3$5.77
    R2$5.67
    R1$5.55
    Pivot Point$5.45
    S1$5.33
    S2$5.23
    S3$5.11

    Advanced Oscillators

    TSI-53.38
    Ultimate Osc32.3
    KST-306.90

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.45M$2.77M$3.08M$2.05M$2.41M$1.45M$0$0$0$0$0$0
    Cost of Revenue$0$0$69,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$2.45M$2.77M$3.08M$2.05M$2.41M$1.45MN/A$0$0$0N/A$0
    Operating Expenses$31.78M$28.15M$31.50M$25.19M$27.18M$17.90M$25.36M$24.75M$15.27M$12.81M$13.60M$9.89M
    R&D$24.36M$20.41M$24.50M$18.51M$19.84M$11.11M$19.23M$20.02M$10.47M$9.32M$10.08M$6.53M
    SG&A$7.42M$7.74M$7.00M$6.68M$7.34M$6.79M$6.14M$4.73M$4.80M$3.49M$3.51M$3.35M
    Operating Income$-29,333,000$-25,375,000$-28,423,000$-23,140,000$-24,771,000$-16,446,000$-25,362,000$-24,750,000$-15,269,000$-12,813,000$-13,596,000$-9,887,000
    Interest Income$3.44M$3.27M$2.79M$3.16M$3.42M$3.71M$4.09M$2.04M$2.20M$1.30M$379,000$499,000
    Interest Expense$1,000$39,000$92,000$149,000$201,000$255,000$319,000$388,000$443,000$1.47M$2.56M$2.40M
    Income Before Tax$-25,896,000$-22,146,000$-25,723,000$-20,129,000$-21,552,000$-12,987,000$-21,280,000$-23,407,000$-13,511,000$-12,984,000$-20,958,000$-14,625,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-26,097,000$-22,253,000$-25,943,000$-20,171,000$-21,563,000$-12,928,000$-21,129,000$-23,407,000$-13,581,000$-12,992,000$-20,958,000$-14,625,000
    EBITDA$-29,826,000$-25,618,000$-28,354,000$-23,091,000$-24,713,000$-16,409,000$-25,315,000$-25,018,000$-15,220,000$-12,780,000$-18,358,000$-12,721,000
    EBIT$-29,333,000$-25,375,000$-28,423,000$-23,140,000$-24,771,000$-16,446,000$-25,362,000$-25,056,000$-15,269,000$-12,813,000$-18,399,000$-12,721,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BIOA

    News

    Deep Origin, BioAge Launch Multi-Target AI-Driven Drug Discovery Collab

    Deep Origin and BioAge Labs have announced an AI-driven drug discovery collaboration aimed at accelerating the development of therapeutic candidates for cardiometabolic diseases. The partnership has already achieved its...

    Contract Pharma•10/14/26•Bullish

    Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target

    Deep Origin has announced a multi-target AI-driven drug discovery collaboration with BioAge Labs, a clinical-stage biopharmaceutical company focusing on cardiometabolic diseases. The partnership leverages Deep Origin's...

    Yahoo Finance Singapore•10/14/26•Bullish

    Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target

    Deep Origin has announced a multi-target AI-driven drug discovery collaboration with BioAge Labs. The partnership aims to accelerate the discovery of novel cardiometabolic therapies by applying Deep Origin's virtual...

    Yahoo Finance•10/14/26•Bullish

    BioAge Labs, Deep Origin Collaborate on AI-Driven Drug Discovery

    BioAge Labs (BIOA) and Deep Origin have announced a new collaboration focused on AI-driven drug discovery for multiple targets. This partnership aims to leverage artificial intelligence to accelerate the identification...

    Yahoo Finance•10/14/26•Bullish

    BioAge Labs, Inc. (BIOA) Has a New Rating from UBS

    UBS has initiated coverage on BioAge Labs, Inc. (BIOA) with a Hold rating and a price target of $8.00. This contrasts with the analyst consensus of a Moderate Buy and a price target of $32.56. The company recently...

    The Globe and Mail•10/13/26•Neutral

    BIOA Valuation and Fair Value

    P/E
    -2.2x
    P/FCF
    -2.7x
    P/B
    0.6x
    See GNG's fair value

    BIOA Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -1197.0%
    Net margin
    0.0%
    ROE
    -28.2%
    FCF margin
    -850.7%
    FCF yield
    -36.7%

    BIOA Competitors

    CompanyTicker
    Century Therapeutics IncIPSC
    So-Young International IncSY
    Inhibikase Therapeutics IncIKT
    Bicycle Therapeutics LtdBCYC
    Vanda Pharmaceuticals IncVNDA
    SAB Biotherapeutics IncSABS
    OraSure Technologies IncOSUR
    Lifecore Biomedical Inc.LFCR

    Sector: Healthcare

    BIOA Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    2
    Buy
    5
    Hold
    2
    Sell
    0
    Strong Sell
    0

    BIOA Bull Case vs Bear Case

    Bull case

    • 77.8% of BIOA's analyst ratings are Buy or Strong Buy.

    Bear case

    • BIOA beat EPS estimates in 37.5% of its last 8 reported quarters.

    BIOA Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -109.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.61
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 1 down

    Frequently Asked Questions About BIOA

    Does BIOA pay dividends?

    BioAge Labs, Inc (BIOA) does not currently pay a regular dividend.

    What is BIOA's market cap?

    BioAge Labs, Inc (BIOA) has a market capitalization of $248.76M with a current stock price of $5.35.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In